Fourth-quarter net revenue increased to $16.6 billion from $15.1 billion in the corresponding period of fiscal 2024. Analysts were expecting a slower top-line growth.
Driven by the strong sales growth, adjusted earnings rose to $2.71 per share in the fourth quarter from $2.16 per share in the year-ago quarter. Net income attributable to the company, on a reported basis, was $1.82 billion or $1.02 per share in Q4, compared to a loss of $22 million or $0.02 per share last year.
The management said it expects adjusted earnings to be in the range of $14.37 per share to $14.57 per share in fiscal 2026.
“2025 was another outstanding year for AbbVie. We delivered record net sales in just the second full year following the U.S. Humira loss of exclusivity, underscoring the strength of our diversified growth platform. We also advanced promising new treatments for patients while enhancing the breadth and depth of our pipeline with strategic investments,” said Robert Michael, CEO of AbbVie.